Quest Diagnostics, Inc. (DGX) Reports In-Line Q3 EPS; Lowers FY12 Outlook
Quest Diagnostics, Inc. (NYSE: DGX) reported Q3 EPS of $1.18, in-line with the analyst estimate of $1.18. Revenue for the quarter came in at $1.9 billion versus the consensus estimate of $1.91 billion.
Sees FY2012 EPS of $4.45-4.55, versus prior guidance of $4.45-4.60 and the consensus of $4.57. Revenues to grow approximately 0.5%, compared to the prior outlook of between 1% and 2%.
For earnings history and earnings-related data on Quest Diagnostics, Inc. (DGX) click here.
Sees FY2012 EPS of $4.45-4.55, versus prior guidance of $4.45-4.60 and the consensus of $4.57. Revenues to grow approximately 0.5%, compared to the prior outlook of between 1% and 2%.
For earnings history and earnings-related data on Quest Diagnostics, Inc. (DGX) click here.